Evidence map›Paper›PMID 42027747›Full record

ArticleBlood neoplasia2026

Single-cell multiomics reveals regulatory mechanisms of CAR T-cell persistence and dysfunction in multiple myeloma.

Lorea Jordana-Urriza, Guillermo Serrano, Sergio Camara-Peña, Maria E Calleja-Cervantes, Patxi San Martin-Uriz, Aintzane Zabaleta, Aina Oliver-Caldes, Marta Español-Rego, Diego Alignani, Teresa Lozano and 21 more

Abstract read
In one paragraph

Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. A 3D engineered multiple myeloma niche for evaluating CAR T cell therapy.Frontiers in bioengineering and biotechnology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Lorea Jordana-UrrizaHemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
Guillermo SerranoComputational Biology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
Sergio Camara-PeñaComputational Biology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
Maria E Calleja-CervantesHemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
Patxi San Martin-UrizHemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
Aintzane ZabaletaHemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
Aina Oliver-CaldesDepartment of Hematology, Hospital Clinic de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.
Marta Español-RegoDepartment of Immunology, Hospital Clinic de Barcelona (HCB), Joint Platform HSJD-HCB, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.
Diego AlignaniHemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
Teresa LozanoImmunology and Immunotherapy Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
Saray Rodriguez-DiazHemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
Elena IglesiasHemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
Valentin CabañasDepartment of Hematology, IMIB-Virgen de la Arrixaca University Hospital, University of Murcia, Murcia, Spain.
Juan L RegueraDepartment of Hematology, University Hospital Virgen del Rocio-IBIS, Universidad de Sevilla, Sevilla, Spain.
Veronica Gonzalez-CalleCentro de Investigacion Biomedica en Red de Cancer, Madrid, Spain.
Maria V MateosCentro de Investigacion Biomedica en Red de Cancer, Madrid, Spain.
Fermin Sanchez-GuijoCentro de Investigacion Biomedica en Red de Cancer, Madrid, Spain.
Bruno PaivaHemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
Juan J LasarteImmunology and Immunotherapy Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
Susana InogesCentro de Investigacion Biomedica en Red de Cancer, Madrid, Spain.
Ascension Lopez-Diaz de CerioCentro de Investigacion Biomedica en Red de Cancer, Madrid, Spain.
Azucena Gonzalez-NavarroDepartment of Immunology, Hospital Clinic de Barcelona (HCB), Joint Platform HSJD-HCB, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.
Manel JuanDepartment of Immunology, Hospital Clinic de Barcelona (HCB), Joint Platform HSJD-HCB, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.
Carlos Fernandez de LarreaDepartment of Hematology, Hospital Clinic de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.
Esteban TamarizCentro de Investigacion Biomedica en Red de Cancer, Madrid, Spain.
Ana Alfonso-PierolaCentro de Investigacion Biomedica en Red de Cancer, Madrid, Spain.
Paula Rodriguez-OteroCentro de Investigacion Biomedica en Red de Cancer, Madrid, Spain.
Jesus F San-MiguelCentro de Investigacion Biomedica en Red de Cancer, Madrid, Spain.
Mikel HernaezComputational Biology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
Juan R Rodriguez-MadozHemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
Felipe ProsperHemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Understanding the mechanisms that drive chimeric antigen receptor (CAR) T-cell function and persistence in multiple myeloma (MM) remains a critical challenge for improving therapeutic outcomes. In this study, we applied single-cell multiomics and gene regulatory network analysis to characterize the transcriptional dynamics and clonal evolution of B-cell maturation antigen-targeted CAR T-cells in longitudinally collected bone marrow (BM) and peripheral blood (PB) samples from patients with MM. Our results revealed that CAR T cells infiltrating BM exhibited a more activated and exhausted phenotype than their PB counterparts, with key transcriptional regulators driving these changes. Dysregulation in the effector-to-memory transition led to increased presence of terminally differentiated CAR T-cells, correlating with poor persistence. Additionally, we identified a hyperexpanded CAR T-cell clone in the BM of a patient in partial response, marked by elevated interleukin-10 (IL-10) expression. Functional analyses demonstrated that stimulation of endogenous T-cell receptor (TCR) enhanced IL-10 production, potentially contributing to impaired CAR T-cell proliferation and persistence. These findings uncover regulatory mechanisms influencing CAR T-cell dynamics, offering new insights into improving CAR T-cell persistence and therapeutic efficacy in MM, and highlight potential molecular targets for optimizing CAR T-cell therapy in patients with MM.

Identifiers

PMID42027747
PMCPMC13101692

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.